Centers For Medicare And Medicaid
HCPs sound off on CMS opioid proposal; Senate committee to decide if Califf gets FDA commissioner nod; Celgene names new CEO
Worldwide spending on cancer medications hit $100 billion last year; Bayer adds an anticoagulant to its pipeline for $100 million; GlaxoSmithKline has a new chairman
The CMS said the issues should be resolved this week and will not affect this month's deadline for companies to submit payment data from 2014.
Centers for Medicare and Medicaid Services says it is too early to blame a sluggish economy for slow growth.
CRS asks if high prices are a tool to offset CMS rebates, the FDA adds another DTC study to its lineup, and the NIH proposes making more clinical trial data public.
Patients have to be high-risk or Baby Boomers for coverage.
CMS could provide more guidance for how to crack down on healthcare fraud, the OIG asserts in a report.
Generics accounted for almost 75% of dispensed drugs in 2012, according to CMS researchers.
CMS is proposing a rule that could change how antidepressants get on Medicare Part D formularies.
The tool lets researchers tap into health data from work, meaning the year-long waits for data are over.
Official numbers are pending, but Reuters notes enrollment appears to be just 3% of the government's goal.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
With a new era of transparency for doctors and life science manufacturers kicking off today, here's how some organizations are keeping physicians informed.
With a clear buffet exemption in-hand, the agency's position with respect to CME meals seems pretty clear. Industry is pushing for more clarity around the treatment of accrediting bodies.
The drug maker asked CMS to approve its Amyvid PET tracer for Medicare beneficiaries, but CMS declined, saying in a draft decision that widespread use would be of little value.
Acting administrator Marilyn Tavenner seems on track for confirmation, with the blessings of all industry stakeholders
Clinical Research Organizations, marketing research firms, accredited CME providers and lawyers look to be the big winners in CMS's Sunshine Act rule.
A BMJ study finds that medical school gift bans make doctors less likely to prescribe a new drug. Also of note: consumers think money motivates some doctors' recommendations.
- Biogen ends Tecfidera DTC campaign, citing prescriptions
- As immuno-oncology therapies evolve, so will the marketing
- GSK Consumer Healthcare to prioritize digital after agency review
- Five things for pharma marketers to know: Thursday, July 21, 2016
- Five things for pharma marketers to know: Tuesday, July 26, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy
- Sponsored Podcast: No Patient Left Behind: Connecting Rare Disease Patients to Orphan Drug Manufacturers
- W2O names Gillespie chief strategy officer of medtech practice
- Five things for pharma marketers to know: Wednesday, July 27, 2016
- DigitasLBi's Carlos Ricque on Why Simple Ads Are the Hardest to Make
- Healthcare marketers: Don't forget about the baby boomers